As we go to press, the FDA has approved nanomicellar preservative-free cyclosporine ophthalmic solution 0.09% (CEQUA, Sun Pharma) to increase tear production in patients who have dry eye disease. The drug is used twice daily and will come in a single-use vial.
The nanomicellar formulation technology employs micelles (gelatinous aggregates of amphipathic — both hydrophobic and hydrophilic — molecules formed at a well-defined concentration) to facilitate the high concentration drug’s entry into corneal and conjunctival cells.
The most common adverse events following instillation were application site pain (22%) and conjunctival hyperemia (6%).
For additional information, visit CEQUA.com . ■
Research Notes
- Batters with better eye-hand visual-motor reaction time may be more likely to reach the major-league baseball level and be more productive for their team, according to July’s Optometry and Vision Science.
- AMD patients who undergo anti-VEGF treatment are at increased risk of having fibrotic scars in the first two years of treatment, with scar development decreasing after two years, reports July’s Ophthalmology.
- Sildenafil (Pfizer) appears to be a safe treatment for age-related and vitelliform macular degenerations, reports a recent study in Ophthalmologica.
- Increased Alzheimer’s disease risk appears correlated with recent glaucoma diagnoses, established AMD diagnoses and both recent and established diabetic retinopathy, reveals the Aug. 2 Alzheimer’s & Dementia.
- Children who have atopic dermatitis (AD) appear to be at high risk for cataracts that require surgery, according to June 7’s JAMA Ophthalmology.
![]({"src":"/media/1bvfoisr/cover_om_0918.jpg","focalPoint":null,"crops":[{"alias":"thumbnail","width":1110,"height":700,"coordinates":null}]})